A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients

1. To gather pilot data on the incidence of autonomic dysfunction in patients with
Multiple Myeloma prior to treatment with Bortezomib.

2. To characterize the changes in the ANS including the fluctuations in blood pressure
(hypotension /hypertension) associated with bortezomib.

3. To determine the duration of the ANS dysfunction if present.

This is not a treatment study, only an evaluation of the autonomic nervous system (ANS)
among subjects receiving antimyeloma therapy which includes bortezomib (Velcade).

Inclusion Criteria:

- Subjects with Active Multiple Myeloma who are scheduled to be treated with
Bortezomib-containing regimens.

- Subjects must have signed an IRB-approved informed consent indicating their
understanding of the proposed treatment and understanding that the protocol has been
approved by the IRB.

Exclusion Criteria:

- Subjects with unstable cardiovascular disease. Recent (< 6 months) myocardial
infarction, unstable angina, difficult to control congestive heart failure,
uncontrolled hypertension, or difficult to control cardiac arrhythmias.

- Subjects unable to perform the Valsalva maneuver such as patients with clinically
significant aortic stenosis, glaucoma or retinopathy.

- Subjects receiving Selective Serotonin Reuptake Inhibitors.